At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from disease. Amgen believes that the cure for disease can be found inside each and every one of us. So, to help people we must focus on people.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen’s medicines treat serious illnesses. We have a presence in more than 75 countries worldwide and have reached millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. Our medicines typically address diseases for which the number of effective treatment options is limited, or they are medicines that provide a viable option to what is otherwise available.
Understanding the fundamental biological mechanisms of human life is a defining feature of Amgen’s discovery research efforts—and a major contributor to the development of Amgen’s deep and broad pipeline of potential new medicines. Amgen’s biology first” approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine or modality is most likely to deliver optimal efficacy and safety. As advances in human genetics continue to shed new light on the molecular roots of disease we expect to continue to improve how we identify and validate human disease targets.
The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.”
Join RI Bio
Join our community to connect with professionals and companies throughout southeast New England.